These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 32790003)

  • 21. Pro- and anti-inflammatory cytokines against Rv2031 are elevated during latent tuberculosis: a study in cohorts of tuberculosis patients, household contacts and community controls in an endemic setting.
    Belay M; Legesse M; Mihret A; Bekele Y; Ottenhoff TH; Franken KL; Bjune G; Abebe F
    PLoS One; 2015; 10(4):e0124134. PubMed ID: 25897840
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Investigation of latent tuberculosis infection in patients with psoriasis who are candidate for receiving immunobiological drugs.
    Lima EV; Lima Mde A; Duarte A; Marques C; Benard G; Lorena V; Gomes Y
    An Bras Dermatol; 2011; 86(4):716-24. PubMed ID: 21987138
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Biologics and mycobacterial diseases].
    Tsuyuguchi K; Matsumoto T
    Kekkaku; 2013 Mar; 88(3):337-53. PubMed ID: 23672175
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor Necrosis Factor-Alpha Antagonist Interferes With the Formation of Granulomatous Multinucleated Giant Cells: New Insights Into
    Mezouar S; Diarra I; Roudier J; Desnues B; Mege JL
    Front Immunol; 2019; 10():1947. PubMed ID: 31475008
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TNF-α/IL-2 ratio discriminates latent from active tuberculosis in immunocompetent children: a pilot study.
    Gourgouillon N; de Lauzanne A; Cottart CH; Curis E; Debord C; Guérin-El Khourouj V; Pédron B; Faye A; Sterkers G
    Pediatr Res; 2012 Oct; 72(4):370-4. PubMed ID: 22797138
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disseminated Tuberculosis in a Psoriasis Patient under Adalimumab Treatment despite the Chemoprophylaxis of Latent Tuberculosis: A Case Report.
    Oh JH; Ham SP; Park HJ
    Ann Dermatol; 2021 Feb; 33(1):77-81. PubMed ID: 33911816
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MicroRNA-889 Inhibits Autophagy To Maintain Mycobacterial Survival in Patients with Latent Tuberculosis Infection by Targeting TWEAK.
    Chen DY; Chen YM; Lin CF; Lo CM; Liu HJ; Liao TL
    mBio; 2020 Jan; 11(1):. PubMed ID: 31992621
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection.
    Tsai TF; Ho V; Song M; Szapary P; Kato T; Wasfi Y; Li S; Shen YK; Leonardi C;
    Br J Dermatol; 2012 Nov; 167(5):1145-52. PubMed ID: 22803615
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice.
    Cantini F; Nannini C; Niccoli L; Iannone F; Delogu G; Garlaschi G; Sanduzzi A; Matucci A; Prignano F; Conversano M; Goletti D;
    Autoimmun Rev; 2015 Jun; 14(6):503-9. PubMed ID: 25617816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A case of latent tuberculosis reactivation in a patient treated with ustekinumab without concomitant isoniazid chemoprophylaxis in the PEARL trial.
    Tsai TF; Chiu HY; Song M; Chan D
    Br J Dermatol; 2013 Feb; 168(2):444-6. PubMed ID: 22816505
    [No Abstract]   [Full Text] [Related]  

  • 31. Clinical applicability of T-cell interferon-a release assay for tumour necrosis factor-a inhibitor therapy in severe psoriasis.
    Chiang YZ; Panting K; Dever B; Parslew RA
    Clin Exp Dermatol; 2011 Jan; 36(1):39-41. PubMed ID: 20456401
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tuberculosis in anti-TNF-α treated patients remains a problem in countries with an intermediate incidence: analysis of 25 patients matched with a control population.
    Abreu C; Magro F; Santos-Antunes J; Pilão A; Rodrigues-Pinto E; Bernardes J; Bernardo A; Magina S; Vilas-Boas F; Lopes S; Macedo G; Sarmento A
    J Crohns Colitis; 2013 Nov; 7(10):e486-92. PubMed ID: 23583099
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The TNF/IL-23/IL-17 axis-Head-to-head trials comparing different biologics in psoriasis treatment.
    Ten Bergen LL; Petrovic A; Krogh Aarebrot A; Appel S
    Scand J Immunol; 2020 Oct; 92(4):e12946. PubMed ID: 32697374
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Infliximab partially impairs the anti-Mycobacterium tuberculosis immune responses of severe psoriasis patients with positive tuberculin skin-test.
    Silva LC; Geluk A; Arnone M; Romiti R; Franken KC; Duarte AJ; Takahashi MD; Benard G
    J Eur Acad Dermatol Venereol; 2012 Mar; 26(3):319-24. PubMed ID: 21623925
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The risk of tuberculosis in Korean patients with inflammatory bowel disease receiving tumor necrosis factor-α blockers.
    Byun JM; Lee CK; Rhee SY; Kim HJ; Kim JW; Shim JJ; Jang JY
    J Korean Med Sci; 2015 Feb; 30(2):173-9. PubMed ID: 25653489
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rates of latent tuberculosis infection in patients treated with TNF inhibitors for psoriasis: a retrospective chart review.
    Lee EB; Amin M; Man J; Egeberg A; Wu JJ
    J Dermatolog Treat; 2018 Nov; 29(7):671-675. PubMed ID: 29455561
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New therapies versus first-generation biologic drugs in psoriasis: a review of adverse events and their management.
    Carrascosa JM; Del-Alcazar E
    Expert Rev Clin Immunol; 2018 Apr; 14(4):259-273. PubMed ID: 29557200
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pulmonary sarcoidosis and latent tuberculosis in a patient with psoriasis treated with adalimumab.
    Korta DZ; Ochieng P; Fishman D; Katz SE
    Dermatol Online J; 2015 Jan; 21(1):. PubMed ID: 25612132
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents).
    Baddley JW; Cantini F; Goletti D; Gómez-Reino JJ; Mylonakis E; San-Juan R; Fernández-Ruiz M; Torre-Cisneros J
    Clin Microbiol Infect; 2018 Jun; 24 Suppl 2():S10-S20. PubMed ID: 29459143
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.